Abstract
Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 565-577 |
| Number of pages | 13 |
| Journal | Expert Opinion on Drug Discovery |
| Volume | 3 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2008 |
Fingerprint
Keywords
- Drug development
- Mycobacterium tuberculosis
- Shikimate kinase
- Shikimate pathway
ASJC Scopus subject areas
- Drug Discovery
Cite this
New tuberculosis drug development : Targeting the shikimate pathway. / Kapnick, Senta M.; Zhang, Ying.
In: Expert Opinion on Drug Discovery, Vol. 3, No. 5, 05.2008, p. 565-577.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New tuberculosis drug development
T2 - Targeting the shikimate pathway
AU - Kapnick, Senta M.
AU - Zhang, Ying
PY - 2008/5
Y1 - 2008/5
N2 - Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.
AB - Background: Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years. Objective: The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria. Methods: New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review. Results/conclusion: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.
KW - Drug development
KW - Mycobacterium tuberculosis
KW - Shikimate kinase
KW - Shikimate pathway
UR - http://www.scopus.com/inward/record.url?scp=44649177007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44649177007&partnerID=8YFLogxK
U2 - 10.1517/17460441.3.5.565
DO - 10.1517/17460441.3.5.565
M3 - Article
VL - 3
SP - 565
EP - 577
JO - Expert Opinion on Drug Discovery
JF - Expert Opinion on Drug Discovery
SN - 1746-0441
IS - 5
ER -